Is Stem Cell Therapy Legal in Japan? Understanding MHLW Regulations

One of the most common questions international patients ask is whether stem cell therapy is actually legal in Japan. The short answer is yes, and Japan has one of the most comprehensive regulatory frameworks for regenerative medicine in the world. Understanding this framework helps patients distinguish legitimate, compliant clinics from those operating in legal grey areas.

The Act on Regenerative Medicine (2014)

Japan's Act on the Safety of Regenerative Medicine (commonly called the Regenerative Medicine Act) took effect on November 25, 2014. This landmark legislation was the first of its kind globally, creating a dedicated legal framework specifically for regenerative medicine therapies including stem cell treatments.

The Act was motivated by Japan's desire to lead in regenerative medicine following Dr. Shinya Yamanaka's Nobel Prize-winning work on induced pluripotent stem cells (iPSCs) at Kyoto University. Rather than fitting stem cell therapies into existing drug or device regulations, Japan created purpose-built legislation.

How the Regulatory System Works

The Japanese regulatory system for stem cell therapy operates on three levels:

• Ministry of Health, Labour and Welfare (MHLW): Sets overall policy, maintains the registry of approved treatment plans, and has enforcement authority.
• Certified Committees for Regenerative Medicine: Independent expert panels that review and approve treatment plans before they can be offered to patients. Each committee includes physicians, scientists, legal experts, and patient advocates.
• Treating Clinics and Physicians: Must submit detailed treatment plans, maintain certified Cell Processing Centers (or contract with certified ones), and report outcomes and adverse events.

Treatment Classification System

Japan classifies regenerative medicine treatments into three risk categories:

• Class I (High Risk): Treatments using iPSCs, embryonic stem cells, or gene-modified cells. These require approval from a Specially Certified Committee and MHLW review.
• Class II (Medium Risk): Treatments using somatic stem cells such as adipose-derived mesenchymal stem cells (MSCs). Most stem cell therapy clinics in Tokyo, including Rakan Clinic, operate under Class II. These require approval from a Certified Committee.
• Class III (Low Risk): Treatments using processed cells that are minimally manipulated, such as PRP (platelet-rich plasma). These require the lowest level of oversight but still must be registered.

This classification system means that the adipose-derived stem cell therapy offered at most Tokyo clinics undergoes meaningful independent review before patients receive it. The Certified Committee examines the scientific rationale, safety protocols, cell processing procedures, physician qualifications, and patient consent processes.

Cell Processing Center (CPC) Requirements

Under the Act, all cell processing for regenerative medicine must occur in facilities that meet specific standards set by MHLW. These Cell Processing Centers must demonstrate:

• Cleanroom environments meeting ISO standards for air quality and particulate control.
• Documented quality management systems for cell handling, culture, and storage.
• Staff trained and certified in cell processing techniques.
• Record-keeping and traceability systems that track every cell product from harvest to administration.
• Regular inspections and audits by regulatory authorities.

Clinics can operate their own in-house CPC (as Rakan Clinic Tokyo does at Azabudai Hills) or contract with external certified CPCs. In-house facilities offer tighter quality control and eliminate transportation risks.

What MHLW Approval Actually Means

When a clinic states it holds MHLW-approved treatment plans, this means it has completed a rigorous multi-step process. The clinic submitted a detailed treatment plan describing the cell type, processing method, administration route, target conditions, patient selection criteria, and safety monitoring protocols. An independent Certified Committee of experts reviewed and approved the plan. The approved plan was registered with MHLW. The clinic must report treatment outcomes and any adverse events to both the Committee and MHLW.

This is not a rubber-stamp process. Committees can and do reject or require modifications to treatment plans. The system creates accountability that protects patients.

How Japan Compares to Other Countries

Japan's approach is distinctive in several ways:

• United States: The FDA regulates stem cells as drugs or biologics. Autologous treatments that involve more than minimal manipulation require a full Biologics License Application, which very few clinics obtain. Many US clinics operate in a regulatory grey area.
• European Union: The EU classifies stem cell products as Advanced Therapy Medicinal Products (ATMPs) under the European Medicines Agency. Regulation varies by member state, creating inconsistency.
• South Korea: Has a conditional approval system that allows some stem cell products to market before completing full clinical trials.
• Southeast Asia: Regulatory frameworks vary widely. Some countries have minimal stem cell-specific regulation, which enables cheaper treatments but with less oversight.

Japan's dedicated legislation means patients receiving stem cell therapy in Tokyo have clearer legal protections than in most other countries.

What Patients Should Verify

Before undergoing stem cell therapy at any Japanese clinic, patients should confirm the following:

• The clinic can provide its MHLW treatment plan registration number.
• The Cell Processing Center is certified and either in-house or a named contracted facility.
• The treating physician is licensed in Japan and has relevant specialty qualifications.
• The informed consent process includes a clear explanation of treatment classification (Class I, II, or III), expected outcomes, risks, and alternatives.
• The clinic has a documented adverse event reporting protocol.

Any legitimate clinic will answer these questions openly. Reluctance to share registration details is a significant warning sign.

Rakan Clinic's Regulatory Standing

Rakan Clinic Tokyo operates under MHLW-approved treatment plans for Class II regenerative medicine. Our in-house CPC at Azabudai Hills is fully certified and undergoes regular inspections. All treating physicians hold Japanese medical licenses with orthopedic and regenerative medicine credentials. We provide every patient with our registration details and a thorough informed consent process before any treatment begins.